Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management.

IF 2.4 3区 医学 Q2 HEMATOLOGY
Jessica C Ding, Celina Montemayor-Garcia, Brie A Stotler, Steven L Spitalnik, José A Ayala Méndez
{"title":"Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management.","authors":"Jessica C Ding, Celina Montemayor-Garcia, Brie A Stotler, Steven L Spitalnik, José A Ayala Méndez","doi":"10.2450/BloodTransfus.750","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rh disease occurs following maternal alloimmunization, which can develop due to RhD blood group antigen incompatibility between a mother and her fetus. Despite developing robust clinical protocols for effective immunoprophylaxis over the last 50+ years, a significant global burden of Rh disease still exists, particularly in low/middle-income countries such as Mexico.</p><p><strong>Materials and methods: </strong>This study examined disparities in the allocation of maternal and child health resources, as well as clinical knowledge regarding Rh disease, to gain insight into why Rh disease remains prevalent in Mexico. To this end, an 11-question survey was sent to members of the Federación Mexicana de Colegios de Obstetricia y Ginecología (FEMECOG) to evaluate their knowledge of the availability and implementation of anti-RhD immunoglobulin prophylaxis in their practices and institutions, and about managing Rh disease by monitoring fetal anemia risk and providing intrauterine treatment when necessary. Responses were separated by region, and chi-square two-by-two contingency tests were performed to evaluate regional and institutional differences.</p><p><strong>Results: </strong>Significant variations in prevention and treatment were found within the Mexican healthcare system, particularly, with regard to providing anti-RhD immunoglobulin to prevent alloimmunization, which is critically important for preventing Rh disease. Specifically, Regions 5, 6, and 7 were most lacking in this regard.</p><p><strong>Discussion: </strong>This study highlights differences in the Mexican healthcare system in preventing and treating Rh disease. Closing the gap in the availability of anti-RhD immunoglobulin should take priority in future efforts aimed at providing equitable care, because this will lead to the more preferable outcome of preventing Rh disease, rather than forcing patients to seek out more complex measures for treating Rh disease after it develops. These data can be used to create strategies to understand and eliminate these healthcare disparities.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2450/BloodTransfus.750","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Rh disease occurs following maternal alloimmunization, which can develop due to RhD blood group antigen incompatibility between a mother and her fetus. Despite developing robust clinical protocols for effective immunoprophylaxis over the last 50+ years, a significant global burden of Rh disease still exists, particularly in low/middle-income countries such as Mexico.

Materials and methods: This study examined disparities in the allocation of maternal and child health resources, as well as clinical knowledge regarding Rh disease, to gain insight into why Rh disease remains prevalent in Mexico. To this end, an 11-question survey was sent to members of the Federación Mexicana de Colegios de Obstetricia y Ginecología (FEMECOG) to evaluate their knowledge of the availability and implementation of anti-RhD immunoglobulin prophylaxis in their practices and institutions, and about managing Rh disease by monitoring fetal anemia risk and providing intrauterine treatment when necessary. Responses were separated by region, and chi-square two-by-two contingency tests were performed to evaluate regional and institutional differences.

Results: Significant variations in prevention and treatment were found within the Mexican healthcare system, particularly, with regard to providing anti-RhD immunoglobulin to prevent alloimmunization, which is critically important for preventing Rh disease. Specifically, Regions 5, 6, and 7 were most lacking in this regard.

Discussion: This study highlights differences in the Mexican healthcare system in preventing and treating Rh disease. Closing the gap in the availability of anti-RhD immunoglobulin should take priority in future efforts aimed at providing equitable care, because this will lead to the more preferable outcome of preventing Rh disease, rather than forcing patients to seek out more complex measures for treating Rh disease after it develops. These data can be used to create strategies to understand and eliminate these healthcare disparities.

墨西哥的 Rh 病:评估地区和机构在提供治疗和疾病管理方面的差异。
背景:Rh 病发生在母体同种免疫之后,这可能是由于母亲和胎儿之间的 RhD 血型抗原不相容造成的。尽管在过去的 50 多年里,为有效的免疫预防制定了健全的临床方案,但 Rh 病仍然给全球带来沉重负担,尤其是在墨西哥等中低收入国家:本研究调查了妇幼保健资源分配的差异以及有关 Rh 病的临床知识,以深入了解 Rh 病在墨西哥仍然流行的原因。为此,我们向墨西哥产科和妇科联盟(FEMECOG)的成员发送了一份包含 11 个问题的调查问卷,以评估他们对其诊所和机构中抗 RhD 免疫球蛋白预防措施的可用性和实施情况的了解,以及对通过监测胎儿贫血风险和必要时提供宫内治疗来控制 Rh 病的了解。结果显示,在预防和治疗方面存在显著差异:结果:发现墨西哥医疗系统在预防和治疗方面存在显著差异,特别是在提供抗 RhD 免疫球蛋白以预防同种免疫方面,这对预防 Rh 病至关重要。具体而言,第 5、第 6 和第 7 地区在这方面最为欠缺:本研究强调了墨西哥医疗系统在预防和治疗 Rh 病方面的差异。缩小抗 RhD 免疫球蛋白供应方面的差距应成为未来提供公平医疗服务的优先事项,因为这将带来预防 Rh 病的更佳结果,而不是迫使患者在患上 Rh 病后寻求更复杂的治疗措施。这些数据可用于制定了解和消除这些医疗差距的战略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Transfusion
Blood Transfusion HEMATOLOGY-
CiteScore
6.10
自引率
2.70%
发文量
91
审稿时长
2 months
期刊介绍: Blood Transfusion welcomes international submissions of Original Articles, Review Articles, Case Reports and Letters on all the fields related to Transfusion Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信